DHR vs NKE: Which Is the Better Buy?

Side-by-side comparison of Danaher Corporation and NIKE, Inc. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-23.
Danaher Corporation Β· Healthcare
$221.12
+29.6% upside to fair value
Med Conviction Grade B High Quality
VS
NIKE, Inc. Β· Consumer Cyclical
$35.78
+9.9% upside to fair value
Med Conviction Grade C
QuantHub Verdict
DHR has more upside to fair value (+29.6%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric DHR NKE
Current Price $221.12 $35.78
Fair Value Estimate $286.52 $39.33
Upside to Fair Value +29.6% +9.9%
Market Cap $155.4B $53.0B
Forward P/E β€” β€”
EV / EBITDA 24.8x 12.0x
Price / Sales 6.2x 1.1x
Price / FCF 28.5x 24.3x
Revenue Growth YoY +5.5% -1.1%
Gross Margin 58.5% 42.9%
Operating Margin 20.4% 8.2%
Return on Equity 7.7% 22.0%
Dividend Yield 0.65% 4.58%
FCF Yield 3.51% 4.12%
Analyst Consensus Strong Buy Hold
Investment Thesis
DHR β€” Danaher Corporation
Danaher is a diversified life-sciences and diagnostics platform spanning three segments: Life Sciences (mass spectrometers, flow cytometry, genomics, bioprocess technologies), Diagnostics (chemistry, immunoassay, microbiology, hematology, molecular and pathology systems), and Environmental & Applied Solutions (water quality and product-identification instrumentation). The business quality is high…
NKE β€” NIKE, Inc.
NIKE designs, markets and distributes athletic footwear, apparel and equipment through the Nike, Jordan and Converse brands, supported by global athlete marketing, valuable intellectual property and a broad wholesale and owned-digital network. Business quality is medium: its brand moat and 22.0% ROE remain meaningful, but the moat is narrowing amid intense competition, weak direct sales and uneve…
Accumulation Zones
Metric DHR NKE
Zone Low $214.89 $29.50
Zone High $243.54 $33.43
In Buy Zone? Yes No
← DHR Research    NKE Research β†’    All Research